Benchmark director to step down
Aquaculture genetics, health and advanced nutrition company Benchmark Holdings has announced that Hugo Wahnish will resign as a non-executive director with effect from 9 February 2021.
Benchmark said Wahnish joined the company in November 2017, bringing more than 35 years of experience in the animal health and pharmaceuticals industry and playing a significant role in Benchmark's transformative period.
During that time Benchmark has sold off what it classed as non-core assets to focus on aquaculture and on commercialising its acquisitions and products.
Restructuring support
Benchmark chair Peter George said: “On behalf of the Board I would like to thank Hugo for his contribution to Benchmark, in particular his support during our restructuring to focus on our core aquaculture areas. We wish him every success in his future endeavours.”
Benchmark supplies ova to the salmon industry from its SalmoBreed operation in Norway and from StofnFiskur in Iceland. It also has a brood stock facility in Chile.
The company is also commercialising its BMK08 lice treatment, based on the neonicotinoid insecticide imidacloprid, which is designed for use in conjunction with its CleanTreat water filter system. The treatment is expected to be authorised for use in Norway in the second quarter of next year.
Benchmark will then seek permission for use in other jurisdictions.
